Evkeeza® (evinacumab) Phase 3 Trial Demonstrates 48% LDL-C Reduction in Children with Ultra-rare Form of High Cholesterol - 21.05.22 - News - ARIVA .DE
BOTSI®-Advisor Hochstufung Teva Pharmaceutical ADR von Rang 401 auf Rang 395 - boerse.de
Press Release: FDA approves Dupixent® (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis - 20.05.22 - News - ARIVA.DE